Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026Appointed Jennifer Riley as Chief Strategy OfficerCash on hand of approximately $135 million as of December 31, 2024 expected to provide runway into…